Morgans Sticks to Their Buy Rating for Resmed Inc CHESS Depositary Interests on a Ratio of 10 CDIs per Ord.sh (RMD)
ResMed Price Target Cut 1.6% to A$48.00/Share by Macquarie
A Quick Look at Today's Ratings for ResMed(RMD.US), With a Forecast Between $240 to $290
ResMed Is Maintained at Overweight by JP Morgan
Piper Sandler Maintains Neutral on ResMed, Lowers Price Target to $248
ResMed Price Target Raised to $274.00/Share From $269.00 by Keybanc
ResMed Analyst Ratings
Stifel Nicolaus Keeps Their Hold Rating on Resmed (RMD)
RBC Raises Price Target on ResMed to $255 From $247, Keeps Sector Perform Rating
KeyBanc Maintains ResMed(RMD.US) With Buy Rating
BofA Securities Maintains ResMed(RMD.US) With Buy Rating, Maintains Target Price $280
Needham Maintains ResMed(RMD.US) With Hold Rating
Analysts Have Conflicting Sentiments on These Healthcare Companies: Edwards Lifesciences (EW), Resmed (RMD) and Thermo Fisher (TMO)
Needham Sticks to Their Hold Rating for Resmed (RMD)
Resmed's Strong Q3 Performance and Strategic Positioning Justify Buy Rating
KeyBanc Sticks to Their Buy Rating for Resmed (RMD)
ResMed Price Target Raised 1.8% to A$45.60/Share by Barrenjoey
KeyBanc Maintains ResMed(RMD.US) With Buy Rating, Cuts Target Price to $268
ResMed Analyst Ratings
KeyBanc Adjusts ResMed Price Target to $269 From $280, Maintains Overweight Rating